Fairtility
AI-powered fertility assessment and treatment optimization platform
Platform · Cloud SaaSCompany source
Company profile
About Fairtility
Fairtility is a company positioned within the Precision Medicine & Genomics sector, with an apparent focus on fertility and reproductive health applications. Based on the limited information available from the website crawl, the company appears to leverage precision medicine approaches to address fertility-related challenges. The company name suggests a combination of 'fair' and 'fertility,' potentially indicating a mission to make fertility treatments or diagnostics more accessible, equitable, or personalized. As a player in the precision medicine space, Fairtility likely employs genomic analysis, data-driven insights, or AI-powered technologies to support reproductive health outcomes. However, specific details about their products, services, technology platform, target customers, and clinical applications require additional information beyond what was captured in the initial website crawl.
Company description Fairtility official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Fairtility?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- fertility
- reproductive health
Who it serves
No customer types are currently listed.
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Decoding embryo development: the effect of clinical variables in morphokinetics and artificial intelligence quality scoring.Reproductive biomedicine online · Jul 1, 2025
Polycystic ovary syndrome and morphokinetic embryonic development: a case-control study evaluating 791 embryos.F&S science · May 1, 2025
Artificial intelligence-driven analysis of embryo morphokinetics in singleton, twin, and triplet pregnancies.Human reproduction (Oxford, England) · Mar 1, 2025
Is there a relationship between morphokinetic parameters and neonatal sex in fresh embryo transfers?Human fertility (Cambridge, England) · Dec 1, 2023
An artificial intelligence algorithm for automated blastocyst morphometric parameters demonstrates a positive association with implantation potential.Scientific reports · Sep 5, 2023
Clinical validation
Clinical-trial records
Data Collection Protocol for the Development of CHLOE-OQ, an AI Model for Assessing Oocytes Quality.NCT06928337 · Sponsor · COMPLETED
Data Collection and Professional Simulated Use Study to Develop an Embryo Quality Artificial Intelligence (AI) ModelNCT07017972 · Sponsor · RECRUITING
Pivotal Observational CHLOE StudyNCT06111365 · Sponsor · COMPLETED
Performance of CHLOE Algorithm on the Prediction of Blastocyst FormationNCT05455281 · Sponsor · COMPLETED
Regulatory
Regulatory records
CHLOE BLASTK243851 · 510k · Aug 15, 2025
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Fairtility
Recent articles published on Fairtility's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.